Join our LinkedIn PATENTSCOPE users Community Group
反馈
设置

设置

查看申请

3,764 个结果
专利局 all 语言 词根提取 false 单一族成员 true 包括NPL false
只有拥有WIPO帐户才能生成RSS源

保存查询

私人查询仅在您登录后对您可见，而不能在RSS 订阅中使用

查询树

优化选项

专利局
全部
指明检索关键词的语言
词根提取功能可将屈折词还原回词根形式。
例如，fishing、fished、fish 和 fisher 这些词都会还原回词根 fish，
因此检索 fisher 即可获得各种变形的所有结果
仅返回专利族的一个成员
在结果中包括非专利文献

完整查询

IC:C07D AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

并排视图快捷键

一般快捷键
转到检索输入栏
CTRL + SHIFT +
转到结果（选定结果）
CTRL + SHIFT +
转到详细信息（选定标签）
CTRL + SHIFT +
转到下一页
CTRL +
转到上一页
CTRL +
结果（首先，执行“转到结果”）
转到下一个结果/图像
/
转到上一个结果/图像
/
向上滚动
Page Up
向下滚动
Page Down
滚动至顶部
CTRL + Home
滚动至底部
CTRL + End
详细信息（首先，执行“转到详细信息”）
转到下一个标签
转到上一个标签

分析

1 / 377
1.WO/2021/217574TREATMENT OR PREVENTION OF CORONAVIRIDAE INFECTION
WO - 04.11.2021
国际分类 C07D 215/46
C化学;冶金
07有机化学
D杂环化合物(高分子化合物入C08)
215杂环化合物,含喹啉或氢化喹啉环系
02环氮原子和非环原子间无键或只有氢原子或碳原子直接连在环氮原子上
16有杂原子或有以3个键与杂原子相连、其中最多以1个键与卤素相连的碳原子,例如,酯基或腈基,直接连在环碳原子上
38氮原子
42连在位置4
46有被氮原子取代的烃基,连在上述氮原子上
 申请号 PCT/CN2020/088241 申请人 WATERSTONE PHARMACEUTICALS (WUHAN) CO., LTD. 发明人 CUI, Jian
A method of treating or preventing a Coronaviridae infection in a subject comprising administrating a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt, ester or prodrug thereof to the subject in need thereof, wherein R1 is OH or H, and the Coronaviridae comprises at least one selected from 2019-nCov virus, HCov 229E virus, SARS virus, MERS virus.
2.20230131564INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION
US - 27.04.2023
国际分类 C07D 207/267
C化学;冶金
07有机化学
D杂环化合物(高分子化合物入C08)
207杂环化合物,含五元环,不与其他环稠合,带1个氮原子作为惟一的环杂原
02只有氢或碳原子直接连在环氮原子上
18环原子间或环原子与非环原子间有1个双键
22有杂原子或有以3个键连杂原子、其中最多以1个键连卤素的碳原子,例如,酯基或腈基,直接连在环碳原子上
24氧或硫原子
262-Pyrrolidones
263只有氢原子或只含氢和碳原子的基直接连在其他环碳原子上
267只有氢原子或只含氢和碳原子的基,直接连在环氮原子
 申请号 17917959 申请人 COCRYSTAL PHAEMA, INC. 发明人 Irina C. Jacobson

Methods of inhibiting the replication of noroviruses and coronaviruses in a biological sample or patient, of reducing the amount of noroviruses or coronaviruses in a biological sample or patient, and of treating norovirus and coronavirus in a patient, comprising administering to said biological sample or patient a safe and effective amount of a compound of Table A, or a pharmaceutically acceptable salt thereof.

3.WO/2022/129210INHIBITION OF VIRUS PROTEASE
WO - 23.06.2022
国际分类 A61K 31/473
A人类生活必需
61医学或兽医学;卫生学
K医用、牙科用或梳妆用的制剂
31含有机有效成分的医药配制品
33杂环化合物
395有氮作为环杂原子的,例如胍乙啶、利福霉素
435有仅以1个氮原子作为环杂原子的六元环的
47喹啉;异喹啉
473与碳环邻位或迫位稠合的,例如吖啶、菲啶
 申请号 PCT/EP2021/085966 申请人 HELMHOLTZ ZENTRUM MUENCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) 发明人 POPOWICZ, Grzegorz Maria
The present invention relates to a composition, comprising at least one compound according to formula (I) as well as to a composition comprising at least one compound according to formula (I) and/or dimers of compounds according to formula (I) in particular for use in the treatment of diseases caused by betacoronaviruses, leishmaniasis, and trypanosomiasis.
4.WO/2021/206799COMPOUNDS FOR THE TREATMENT OF SARS
WO - 14.10.2021
国际分类 A61K 31/404
A人类生活必需
61医学或兽医学;卫生学
K医用、牙科用或梳妆用的制剂
31含有机有效成分的医药配制品
33杂环化合物
395有氮作为环杂原子的,例如胍乙啶、利福霉素
40有仅以1个氮作为环杂原子的五元环的,例如舒必利、琥珀酰亚胺、托尔米丁、甲氧吡丁苯
403与碳环稠合的,例如咔唑
404吲哚类,例如吲哚洛尔
 申请号 PCT/US2021/017271 申请人 PURDUE RESEARCH FOUNDATION 发明人 MITSUYA, Hiroaki
Bis-amide inhibitors of SARS-CoV-2 (COVID), pharmaceutical compositions comprising same; and methods of treating a severe acute respiratory syndrome.
5.2021105627In silico evaluation and synthesis of novel sulfonamides as promising anti-viral drugs docked against anti-COVID-19 protein targets: SARS-CoV-2 main protease
AU - 28.10.2021
国际分类 C07D 295/26
C化学;冶金
07有机化学
D杂环化合物(高分子化合物入C08)
295杂环化合物,含多亚甲基亚胺环,最少有五元环,3-氮杂二环-壬烷,哌嗪,吗啉或硫吗啉环,仅有氢原子直接连在环碳原子上
22有杂原子直接连在环氮原子上
26硫原子
 申请号 2021105627 申请人 Bobbala, Prathima DR 发明人 Bobbala, Prathima
COVID-19 pandemic has led us to design and develop novel organic molecules as medicinally promising drugs which can prevent the SARS-CoV-2 virus of the infected patients. The current invention provides potential anti-viral drugs docked against anti COVID-19 protein targets: SARS-CoV-2 main protease, drug-likeness, efficacy, molecular docking, physicochemical and pharmacokinetic studies of novel synthesized sulfonamide analogues. Physicochemical and pharmacokinetic properties have been evaluated on the basis of certain parameters like Lipinski rule of 5 (RO5 rule) and ADMET (absorption, distribution, metabolism, excretion and toxicity). All the synthesized compounds follow Lipinski rule of five (RO5 rule) and the compounds followed the range of rotational bonds, hydrogen bond acceptors (HBA), hydrogen bond donors (HBD), topological surface area (TPSA), number of violations, etc. All these compounds shown good pharmacokinetic properties, zero renal OCT2 substrate toxicity and negligible toxicity values. BOILED-egg model was carried out for evaluating the gastrointestinal absorption and brain penetration effect. Compounds 3b and 3d comes under white region of egg and exhibited good gastrointestinal absorption, whereas, 3a, 3c, 3e and 3f compounds fall under yellow region (yolk) of egg which showed good brain penetration effect. All novel sulfonamide analogues including commercially available anti-COVID-19 drugs, Hydroxychloquine and Umifenovir docked with anti-COVID-19 protein targets, i.e., PDB: 6VWW & 6Y2E. Compound 3c when docked with PDB: 6VWW shown maximum energy of -22.06 kcal/mol with two hydrogen binding interactions which are better than marketed drugs. Similarly, compound 3a exhibited highest energy of-14.00kca/mol.
6.20220227776PRODRUGS OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGUES FOR ANTIVIRAL TREATMENT
US - 21.07.2022
国际分类 C07D 487/04
C化学;冶金
07有机化学
D杂环化合物(高分子化合物入C08)
487在稠环系中含有氮原子作为仅有的杂环原子的杂环化合物,不包含在C07D451/00至C07D477/00组中
02在稠合系中含有两个杂环
04邻位稠合系
 申请号 17712635 申请人 Copycat Sciences Inc. 发明人 Victoria Yan

The present invention provides novel compounds and pharmaceutically acceptable salts or esters thereof. For example, the compound has the structure of Formula V. Also provided is a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt or ester thereof and a pharmaceutically acceptable carrier. Further provided a method for inhibiting a polymerase of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (SARS-CoV-2 polymerase) or treating viral infection in a subject in need thereof, comprising administering an effective amount of the pharmaceutical composition to the subject, for example, orally.

7.WO/2022/251647INHIBITORS OF SARS-COV-2 VIRAL REPLICATION AND USES THEREOF
WO - 01.12.2022
国际分类 C07D 239/96
C化学;冶金
07有机化学
D杂环化合物(高分子化合物入C08)
239杂环化合物,含1,3-二嗪环或氢化1,3-二嗪环
70与碳环或碳环系稠合
72喹唑啉;氢化喹唑啉
95有杂原子直接连在位置2和4
96两个氧原子
 申请号 PCT/US2022/031360 申请人 ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA 发明人 CHANG, Rui
This invention is in the field of medicinal pharmacology. In particular, the present invention relates to pharmaceutical agents which function as inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral replication and/or SARS-CoV-2 related viral 3CL protease (Mpro) activity, which function as therapeutics for the treatment of conditions caused by the SARS-CoV-2 virus (e.g., COVID-19), and which function as therapeutics for the treatment conditions related to SARS-CoV-2 related Mpro activity.
8.20240043417COMPOUNDS FOR THE TREATMENT OF SARS
US - 08.02.2024
国际分类 C07D 417/14
C化学;冶金
07有机化学
D杂环化合物(高分子化合物入C08)
417杂环化合物,含两个或更多个杂环、至少有1个环有氮原子和硫原子作为仅有的杂环原子,C07D415/00组不包含的
14含有3个或更多个杂环
 申请号 18255339 申请人 Purdue Research Foundation 发明人 Arun K. Ghosh

Bis-amide inhibitors of SARS-CoV-2 (COVID) and methods of using them to treat a severe acute respiratory syndrome.

9.20220396550Compounds for the treatment of SARS
US - 15.12.2022
国际分类 C07D 207/26
C化学;冶金
07有机化学
D杂环化合物(高分子化合物入C08)
207杂环化合物,含五元环,不与其他环稠合,带1个氮原子作为惟一的环杂原
02只有氢或碳原子直接连在环氮原子上
18环原子间或环原子与非环原子间有1个双键
22有杂原子或有以3个键连杂原子、其中最多以1个键连卤素的碳原子,例如,酯基或腈基,直接连在环碳原子上
24氧或硫原子
262-Pyrrolidones
 申请号 17826061 申请人 Purdue Research Foundation 发明人 Arun K. Ghosh

Inhibitors of SARS-CoV-2 (COVID), pharmaceutical compositions comprising same; and methods of treating a severe acute respiratory syndrome.

10.WO/2023/102653GLYCOGEN SYNTHASE KINASE-3 (GSK3) INHIBITOR COMPOUNDS FOR USE AS ANTIVIRAL AGENTS
WO - 15.06.2023
国际分类 C07D 413/04
C化学;冶金
07有机化学
D杂环化合物(高分子化合物入C08)
413杂环化合物,含两个或更多个杂环,至少有1个环有氮原子和氧原子作为仅有的杂环原子
02含两个杂环
04被环原子-环原子的键直接连接的
 申请号 PCT/CA2022/051784 申请人 THE UNIVERSITY OF BRITISH COLUMBIA 发明人 AV-GAY, Yossef
Provided herein are compounds that inhibit glycogen synthase kinase-3 (GSK3) giving them antiviral activity. In particular, the invention relates to a subset of compounds represented by Formulas (I) and (II), for use as antiviral agents in the treatment or prevention of viral infection. Methods for using the GSK3 inhibitor compounds in the treatment or prophylaxis of a viral infection are provided. In particular, the viral infection may be selected from one or more of the following: Severe Acute Respiratory Syndrome (SARS) coronavirus- 1 SARS-CoV-1) infection; SARS coronavirus-2 (SARS-CoV-2) infection; and Middle East Respiratory Syndrome (MFRS) coronavirus (MERS-CoV) infection. More specifically, the viral infection may be a human coronavirus 229E (HCoV-229E) infection.
# -